Medindia

X

Gene Therapy in Modified Delivery System Reduces Cancer Risk

by Julia Samuel on  November 5, 2016 at 9:04 AM Cancer News   - G J E 4
Development of cancer cells that are an infrequent but dangerous byproduct of gene therapy can now be reduced.
Gene Therapy in Modified Delivery System Reduces Cancer Risk
Gene Therapy in Modified Delivery System Reduces Cancer Risk
Advertisement

Grant Trobridge, an associate professor of pharmaceutical sciences, has altered the way a virus carries a beneficial gene to its target cell. The modified viral vectors reduce the risk of cancer and can be used for many blood diseases.

‘A vector developed from a foamy retrovirus is used in gene therapy to treat SCID-X1 by replacing defective genes with repaired ones.’
Advertisement
Trobridge and his team report their development in Scientific Reports, an online open-access journal produced by the Nature Publishing Group. The team is translating their findings into a stem cell gene therapy to target a life-threatening immunodeficiency in newborns called SCID-X1, also known as "Boy in the Bubble Syndrome."

Gene therapy holds potential for treating genetic diseases by replacing defective genes with repaired ones. It has shown promise in clinical trials but has also been set back by difficulties delivering genes, getting them to work for a long time and safety issues. A joint French and English trial, for example, successfully treated 17 out of 20 patients with SCID-X1 only to see five of them develop leukemia.

Trobridge and his colleagues are using a vector developed from a foamy retrovirus, so named because it appears to foam in certain situations. Unlike other retroviruses, they don't normally infect humans. They also are less prone to activate nearby genes, including genes that might cause cancer.

Retroviruses are a natural choice for gene therapy because they work by inserting their genes into a host's genome. With an eye toward making the vector safer, the Trobridge team altered it to change how it interacts with a target stem cell so it would insert itself into safer parts of the genome. They found that it integrated less often near potential cancer-causing genes.

"Our goal is to develop a safe and effective therapy for SCID-X patients and their families," said Trobridge. "We've started to translate this in collaboration with other scientists and medical doctors into the clinic." He predicted that the therapy could be ready for clinical trials within five years.

Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All